my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
08-10-2007: As part of its commitment to improving access to medicines, GlaxoSmithKline announced it has given consent through Canada's Access to Medicines Regime to enable a Canadian company (Apotex) to manufacture a generic fixed dose combination (FDC) antiretroviral (ARV), containing two molecules over which GSK has patent rights (zidovudine and lamivudine) for the treatment of HIV/AIDS in Rwanda.
Canada's Access to Medicines Regime reflects the WTO "31f" agreement of August 2003 and enables the government to authorise the production of certain patented medicines for export. The legislation includes controls which are designed to ensure that these essential medicines reach the patients for whom they are intended and the authorisation to be granted will be subject to these controls. GSK has agreed to waive royalties on the basis that Apotex's triple combination generic ARV will be supplied on a no profit basis.
Paul Lucas, President and CEO, GSK Canada said, "Tackling the AIDS crisis is one of the greatest challenges the world faces. GSK continues to play its part to tackle this crisis through research and development, not-for-profit pricing and ongoing investment in dedicated community programmes. Our decision to allow Apotex to manufacture an FDC containing two GSK molecules is part of this broad commitment. It also shows that Canada's Access to Medicines Regime operates effectively to enable supply of medicines from Canada as envisaged under the 31f Agreement."
Watchlist
This is where you can add this news to your personal favourites
A consortium of GlaxoSmithKline (GSK), Green Biologics and the Centre for Processing Innovation (CPI), led by Stratophase, is developing a cost-effective, multi-parametric sensor system for increasing the efficiency of high-value liquid based production processes. The £1.2m APPLES (Advance ... more
GlaxoSmithKline announces USD 1.65 billion of acquisition Reliant Pharmaceutical
Pronova BioPharma ASA notes the announcement of a proposed USD 1.65 billion acquisition between GlaxoSmithKline PLC and Reliant Pharmaceuticals, Inc. GlaxoSmithKline is one of the world`s leading research-based pharmaceutical and healthcare companies and its proposed acquisition of Reliant, ... more
Anacor Pharmaceuticals and GlaxoSmithKline announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialization of novel medicines for viral and bacterial diseases. The collaboration provides GlaxoSmithKline access to Anacor's proprietary ... more
Apotex Makes 2nd Acquisition in Europe by Purchasing Lareq Pharma of Spain
Apotex Inc., announced that it has acquired Lareq Pharma S.L. of Spain for an undisclosed sum from Industria Quimica Y Farmaceutica VIR S.A. Lareq, founded in 1984 and dedicated to generics since 1996, is a mid-sized generic pharmaceutical company. With 12 generic registrations, several pe ... more
As part of its commitment to improving access to medicines, GlaxoSmithKline announced it has given consent through Canada's Access to Medicines Regime to enable a Canadian company (Apotex) to manufacture a generic fixed dose combination (FDC) antiretroviral (ARV), containing two molecules o ... more
Sanofi-aventis and Bristol-Myers Squibb Company announced that they have reached an agreement subject to certain conditions with Apotex Inc. and Apotex Corp. to settle the patent infringement lawsuit pending between the parties in the U.S. District Court for the Southern District of New Yor ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
